The relative ability of human papillomavirus type 6 and human papillomavirus type 16 E7 proteins to transactivate E2F-responsive elements is promoter- and cell-dependent

Virology

Volumn 239, Issue 1, 1997, Pages 238-246

  Armstrong, Deborah J ^a   Roman, Ann ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL STRAIN COS1; CONTROLLED STUDY; HUMAN; HUMAN CELL; KERATINOCYTE; KIDNEY CELL; NEWBORN; NONHUMAN; PREPUCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; RAT; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; VIRUS CARCINOGENESIS; WART VIRUS;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPES; PAPOVAVIRIDAE;

EID: 0031471458     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8885     Document Type: Article

References (58)

1. Adams P. D., Kaelin W. G. Jr. The cellular effects of E2F overexpression. Curr. Top. Microbiol. Immunol. 208:1996;79-93.
2. D. J. Armstrong, 1995, Indiana University.
3. Armstrong D. J., Roman A. Mutagenesis of human papillomavirus types 6 and 16 E7 open reading frames alters the electrophoretic mobility of the expressed proteins. J. Gen. Virol. 73:1992;1275-1279.
4. Armstrong D. J., Roman A. The anomalous electrophoretic behavior of the human papillomavirus type 16 E7 protein is due to the high content of acidic amino acid residues. Biochem. Biophys. Res. Commun. 192:1993;1380-1387.
5. Armstrong D. J., Roman A. Human papillomavirus type 6 E7 protein is a substrate in vitro of protein kinase C. Biochem. J. 312:1995;667-670.
6. Arroyo M., Bagchi S., Raychaudhuri P. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol. Cell. Biol. 13:1993;6537-6546.
7. Banks L., Edmonds C., Vousden K. H. Ability of the HPV 16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene. 5:1990;1383-1389.
8. Barbosa M. S., Edmonds C., Fisher C., Schiller J. T., Lowy D. R., Vousden K. H. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and SV40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 9:1990;153-160.
9. Boyer S. N., Wazer D. E., Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteosome pathway. Cancer Res. 56:1996;4620-4624.
10. Brokaw J. L., Yee C. L., Munger K. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein. Virology. 205:1994;603-607.
11. Carlotti F., Crawford L. Trans-activation of the adenovirus E2 promoter by human papillomavirus type 16 E7 is mediated by retinoblastoma-dependent and -independent pathways. J. Gen. Virol. 74:1993;2479-2486.
12. Chen C., Okayama H. High efficiency transformations of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:1987;2745-2752.
13. Cheng S., Schmidt-Grimminger D.-C., Murant T., Broker T. R., Chow L. T. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9:1995;2335-2349.
14. Ciccolini F., Di Pasquale G., Carlotti F., Crawford L., Tommasino M. Functional studies of E7 proteins from different HPV types. Oncogene. 9:1994;2633-2638.
15. Cobrinik D. Regulatory interactions among E2Fs and cell cycle control proteins. Curr. Top. Microbiol. Immunol. 208:1996;31-61.
16. 1. Mol. Cell. Biol. 15:1995;4215-4224.
17. Demers G. W., Espling E., Harry J. B., Etscheid B. G., Galloway D. A. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J. Virol. 70:1996;6862-6869.
18. Demers G. W., Foster S. A., Halbert C. L., Galloway D. A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16E7. Proc. Natl. Acad. Sci. USA. 91:1994;4382-4386.
19. de Wet J. R., Wood K. V., De Luca M., Helinski D. R., Subramani S. Firefly luciferase gene: Structure and expression in mammalian cells. Mol. Cell. Biol. 7:1987;725-737.
20. Dollard S. C., Broker T. R., Chow L. T. Regulation of the human papillomavirus type 11 E6 promoter by viral and host transcription factors in primary human keratinocytes. J. Virol. 67:1993;1721-1726.
21. Durst M., Gissmann L., Ikenberg H., zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. USA. 80:1983;3812-3815.
22. Edmonds C., Vousden K. H. A point mutational analysis of human papillomavirus type 16 E7. J. Virol. 63:1989;2650-2656.
23. Farr A., McAteer J. A., Roman A. Transfection of human keratinocytes with pRSVcat and human papillomavirus type-6 DNA. Cancer Cells. 5:1987;171-177.
24. Farr A., Wang H., Kasher M. S., Roman A. Relative enhancer activity and transforming potential of authentic human papillomavirus type 6 genomes from benign and malignant lesions. J. Gen. Virol. 72:1991;519-526.
25. Firzlaff J. M., Galloway D. A., Eisenman R. N., Luscher B. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol. 1:1989;44-53.
26. Firzlaff J. M., Luscher B., Eisenman R. N. Negative charge at the casein kinase II phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16. Proc. Natl. Acad. Sci. USA. 88:1991;5187-5191.
27. Gage J. R., Meyers C., Wettstein F. O. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol. 64:1990;723-730.
28. Geng Y., Eaton E. N., Picon M., Roberts J. M., Lundberg A. S., Gifford A., Sardet C., Weinberg R. A. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene. 12:1996;1173-1180.
29. Gluzman Y. SV40-transformed simian cells support the replication of early SV40 mutants. Cell. 23:1981;175-182.
30. Gulliver G., Herber R., Liem A., Lambert P. F. Both the CR1 and CR2 domains of E7 are required for its capacity to induce epithelial hyperplasia and tumors in vivo. J. Virol. 71:1997;5905-5914.
31. Halbert C. L., Demers G. W., Galloway D. A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:1991;473-478.
32. Heck D. V., Yee C. L., Howley P. M., Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. USA. 89:1992;4442-4446.
33. Hu T., Ferril S. C., Snider A.-M., Barbosa M. S. In vivo analysis of HPV E7 protein association with pRb, p107, and p130. Intl. J. Oncol. 6:1995;167-174.
34. Hurford R. K., Cobrinik D., Lee M.-H., Dyson N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev. 11:1997;1447-1463.
35. Imperiale M. J., Hart R. P., Nevins J. R. An enhancer-like element in the adenovirus E2 promoter contains sequences essential for uninduced and E1A-induced transcription. Proc. Natl. Acad. Sci. USA. 82:1985;381-385.
36. Jones D. L., Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J. Virol. 71:1997;2905-2912.
37. Lam E. W.-F., Bennett J. D., Watson R. J. Cell-cycle regulation of human B-myb transcription. Gene. 16:1995;277-281.
38. Lam E. W.-F., Morris J. D. H., Davies R., Crook T., Watson R. J., Vousden K. H. HPV16 E7 oncoprotein deregulates B-myb expression: Correlation with targeting of p107/E2F complexes. EMBO J. 13:1994;871-878.
39. Lam E. W.-F., Watson R. J. An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J. 12:1993;2705-2713.
40. Loeken M. R., Brady J. The adenovirus enhancer. Analysis of regulatory sequences and changes in binding activity of ATF and EIIF following adenovirus infection. J. Biol. Chem. 264:1989;6572-6579.
41. Massimi P., Pim D., Storey A., Banks L. HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene. 12:1996;2325-2330.
42. Munger K., Yee C. L., Phelps W. C., Pietenpol J. A., Moses H. L., Howley P. M. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65:1991;3943-3948.
43. Pattison S., Skalnik D. G., Roman A. CCAAT displacement protein, a regulator of differentiation-specific gene expression, binds a negative regulatory element within the 5′ end of the human papillomavirus type 6 long control region. J. Virol. 71:1997;2013-2022.
44. Phelps W. C., Bagchi S., Barnes J. A., Raychaudhuri P., Kraus K., Munger K., Howley P. M., Nevins J. R. Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism. J. Virol. 65:1991;6922-6930.
45. Phelps W. C., Munger K., Yee C. L., Barnes J. A., Howley P. M. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol. 66:1992;2418-2427.
46. Phelps W. C., Yee C. L., Munger K., Howley P. M. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell. 53:1988;539-547.
47. Phillips A. C., Vousden K. H. Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein, TBP. J. Gen. Virol. 78:1997;905-909.
48. Scheffner M., Munger K., Byrne J. C., Howley P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA. 88:1991;5523-5527.
49. Slansky J. E., Farnham P. J. Transcriptional regulation of the dihydrofolate reductase gene. BioEssays. 18:1996;55-62.
50. Storey A., Almond N., Osborn K., Crawford L. Mutations of the human papillomavirus type 16 E7 gene that affect transformation, transactivation and phosphorylation by the E7 protein. J. Gen. Virol. 71:1990a;965-970.
51. Storey A., Osborn K., Crawford L. Co-transformation by human papillomavirus types 6 and 11. J. Gen. Virol. 71:1990b;165-171.
52. Storey A., Pim D., Murray A., Osborn K., Banks L., Crawford L. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J. 7:1988;1815-1820.
53. Thierry F., Yaniv M. The BPV1-E2 trans-acting protein can be either an activator or a repressor of the HPV 18 regulatory region. EMBO J. 6:1987;3391-3397.
54. van der Eb A. J., Graham F. L. Assay of transforming activity of tumor virus DNA. Methods Enzymol. 65:1980;826-839.
55. Vousden K. H., Doniger J., DiPaolo J. A., Lowy D. R. The E7 open reading frame of human papillomavirus 16 encodes a transforming gene. Oncogene Res. 3:1988;167-175.
56. Watanabe S., Kanda T., Sato H., Furuno A., Yoshiike K. Mutational analysis of human papillomavirus type 16 E7 functions. J. Virol. 64:1990;207-214.
57. Watanabe S., Sato H., Komiyama N., Kanda T., Yoshiike K. The E7 functions of human papillomaviruses in rat 3Y1 cells. Virology. 187:1992;107-114.
58. Wu E. W., Clemens K. E., Heck D. V., Munger K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J. Virol. 67:1993;2402-2407.